New Test to replace Cologuard. It's Over!!!

Discussion in 'Exact Sciences' started by anonymous, Jan 10, 2016 at 10:04 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Genetic sequencing firm Illumina Inc. has formed a new company to develop a cancer-screening blood test, with investments from tech billionaires Bill Gates and Jeff Bezos.
    The new company, to be called Grail, has more than $100 million in funding from Illumina, Arch Venture Partners, Sutter Hill Ventures, Bezos Expeditions and Gates, according to a statement on Sunday.
    Grail’s goal is to create a “pan-cancer” screening test that can diagnose people at a very early stage even when they have no symptoms, said Jay Flatley, Illumina’s chief executive officer, in a telephone interview. “This is a massive market,” he said. “Depending on your assumptions, it’s somewhere between a $20 billion and $200 billion market opportunity.”
    As the startup’s name implies, such a test is a much-sought and elusive goal for the industry. Using a blood sample to screen for cancer is an increasingly popular idea because blood draws are far cheaper and less invasive than traditional biopsies.
    Good news for human beings, but I hate to say this: NOT GOOD for EXAS
     

  2. anonymous

    anonymous Guest

    This company is hiring. Will take a look.
     
  3. anonymous

    anonymous Guest

    LMAO replace give me a freakin break ! CG is a glorified stool test that hardly anybody gives a crap about. It is DOA already !
     
  4. anonymous

    anonymous Guest

    Yeah old news, most companies are there.. exas has identified emerging blood tests as a threat in their public business plan online..

    Umm.. News flash .. "EXAS shares reportedly were weak due to the news that colon cancer test competitor Epigenomics expects FDA to decide on Epi proColon test in next few months"i
     
  5. anonymous

    anonymous Guest

     
  6. anonymous

    anonymous Guest

     
  7. anonymous

    anonymous Guest

    Hey Sparky! Maybe you should have read the whole article! “It remains to be proven,” Nelsen asserts, “but it’s likely to be the case that you will be able to know deep and large amounts of information about multiple cancers with a single test.”
    Maybe sometime in the future? But for now Cologuard is it.
     
  8. anonymous

    anonymous Guest

    Illumina is light yrs ahead of this shit in a bucket company
     
  9. anonymous

    anonymous Guest

    So true.
     
  10. anonymous

    anonymous Guest

    What remains to be proven? There are better tests coming out that are blood based versus shit? I think this reas "FDA approval next few months" sparky.. You should apply
     
  11. anonymous

    anonymous Guest

    "And for now, this test doesn’t even really exist. Flatley is confident it will within a year. GRAIL has to talk to the FDA. It needs a CEO. Klausner, the former NCI chief, is leaving Illumina, but remaining with GRAIL as a director." Here ya go DA.... MAYBE you should have read the entire article!
     
  12. anonymous

    anonymous Guest

    Not talking about illumina "sparky"..do not detract ..
     
  13. anonymous

    anonymous Guest

    epigenomics -you should verse yourself better with the next competitor..
     
  14. anonymous

    anonymous Guest

    It is positive though to be able to interpret and summarize the article several times, just the wrong one! Certainly Resorting to names like DA is childish. Just sharing competive info
     
  15. anonymous

    anonymous Guest

    No mention of this on EXAS message board for years.
     
  16. anonymous

    anonymous Guest

    Where have you been? Blood tests aren’t a new area of focus. We’re even working on them at Exact. CG has a limited window. We know it and will probably be the first company to come up with a replacement product. Not a surprise at all. Come back with actual news next time.
     
  17. anonymous

    anonymous Guest

    exact sucks.
    buying pathetic low grapes which provide no value.
     
  18. anonymous

    anonymous Guest

    The constant acquisition of new companies is the only way to hide the underperformance. We can keep pretending the lack of profitability is due to the acquisition.